23
JAN
2015
Fragile X discovery

Rare case uncovers missing clue to Fragile X

Here is another clue to the Fragile X Syndrome mystery, discovered by Dr. Vitaly Klyachko, a professor at Washington University School of Medicine in St. Louis, along with...
13
JAN
2015

Mark Bear shows mGluR5 blockers correct problems in autism model

FRAXA Scientific Advisor and researcher Mark Bear, author of the mGluR Theory of Fragile X, has now shown that mGluR5 blockers can correct memory problems in a new mouse model...
30
DEC
2014
Neuren Pharmaceuticals

Neuren seeks orphan drug status for Rett Syndrome treatment

Neuren seeks orphan drug status for Rett Syndrome treatment Neuren Pharmaceuticals (ASX:NEU) has submitted applications to the US Food and Drug Administration (FDA) for Orphan...
22
DEC
2014

Family’s Search For Fragile X Drug Finds Frustration, Hope

A Family’s Long Search For Fragile X Drug Finds Frustration, Hope on NPR Morning Edition by Jon Hamilton Read or listen here:...
22
DEC
2014
Fragile X Student teams at WPI help FRAXA Research Foundation

Students at WPI helping FRAXA Research Foundation

Students at WPI helping FRAXA Research Foundation Undergraduate students at Worcester Polytechnic Institute (WPI) complete what is known as the Interactive Qualifying Project...
12
DEC
2014
Elizabeth Berry-Kravis, MD, PhD

Informational webinar: Clinical trial of Alcobra’s MDX in Fragile X Syndrome

Clinical trial of Alcobra’s MDX in ages 15-55 with Fragile X Syndrome Webinar presented by Elizabeth Berry-Kravis, MD, PhD Rush University Medical Center Alcobra is...
26
NOV
2014
Fragile X compound from Neuren

Neuren’s NNZ-2566 shows clinical benefit in Rett syndrome trial

Neuren’s NNZ-2566 shows clinical benefit in Rett syndrome trial Promising results in Phase 2 clinical trial by Michael Tranfaglia, MD FRAXA Medical Director This isn’t a...
18
NOV
2014
synapse Fragile X

FRAXA Grants and Fellowships for Fragile X Research – 2015 Priorities

Funding Priorities for Feb 2, 2015 FRAXA Grant Cycle While FRAXA Research Foundation’s research goals remain largely unchanged, the landscape in which we operate has changed...
share this Email this to someoneShare on FacebookShare on LinkedInTweet about this on TwitterShare on Google+Pin on PinterestShare on StumbleUpon